A neuroscientist whose studies undergird an experimental Alzheimer’s drug was “reckless” in his failure to keep or provide original data, an offense that “amounts to significant research misconduct,” an investigation by his university has concluded.The drug, simufilam, is made by Cassava Sciences, a pharmaceutical company based in Texas, and is in advanced clinical trials. The…
